A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84

• Protocol code: SPL84-002
• EudraCT code: No aplica
• Research group: Pneumology
• Service: Pneumology
• Principal investigator:  Álvarez Fernandez, Antonio
• Pathology: Malalties del sistema respiratori
• Phase: Fase II
• Status: Recruiting volunteers

Estudio fase IIb, aleatorizado, doble ciego, controlado con placeboy con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad deAZD5004 en adultos con diabetes mellitus tipo 2

• Protocol code: D7261C00001
• EudraCT code: No aplica
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Ciudin Mihai, Andreea
• Pathology: Malalties endocrines, nutricionals i metabòliques
• Phase: Fase II
• Status: Recruiting volunteers

“Efficacy and safety of co administered cagrilintide and semaglutide(CagriSema) once weekly versus placebo in participants with type 2diabetes and painful diabetic peripheral neuropathy

• Protocol code: NN9388-7864
• EudraCT code: No aplica
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Ortiz Zuñiga, Angel Michael
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II
• Status: Recruiting volunteers

Estudio de fase 3, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con VIH-1 con supresión virológica bajo tratamiento con bictegravir/emtricitabina/tenofovir (B/F/TAF)

• Protocol code: GS-US-563-5925
• EudraCT code: No aplica
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Curran Fàbregas, Adria
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase III
• Status: Recruiting volunteers

' Efficacy and safety of co-administered cagrilintide and semaglutide(CagriSema 2.4 mg/2.4 mg) once-weekly versus semaglutide 2.4 mg,cagrilintide 2.4 mg and placebo in people with chronic kidneydisease and type 2 diabetes living with overweight or obesity.'

• Protocol code: NN9388-7700
• EudraCT code: No aplica
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Soler Romeo, Maria Jose
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II
• Status: Recruiting volunteers

Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de anifrolumab en adultos con lupus eritematoso cutáneo subagudo o crónico que son resistentes o intolerantes al tratamiento antipalúdico

• Protocol code: D346BC00001
• EudraCT code: No aplica
• Research group: Rheumatology
• Service: Rheumatology
• Principal investigator:  Cortes Hernandez, Josefina
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment.

• Protocol code: JZP598-303
• EudraCT code: 2023-508960-31
• Service: Oncology
• Principal investigator:  Escriva de Romaní Muñoz, Santiago Ignacio
• Pathology: Tumors
• Phase: Fase III
• Status: Recruiting volunteers